947533-45-1 Usage
Uses
Used in Pharmaceutical Industry:
2-Bromo-5-fluoropyrimidine is used as a key intermediate for the synthesis of new therapeutic drugs. Its unique reactivity allows for the creation of a diverse range of pharmaceutical compounds, potentially leading to the development of novel treatments for various medical conditions.
Used in Organic Chemistry Research:
In the realm of organic chemistry, 2-Bromo-5-fluoropyrimidine is employed as a building block for the construction of more complex molecules. Its reactivity with other chemical entities makes it a valuable component in the synthesis of advanced organic compounds, which can be utilized in various applications, including materials science and medicinal chemistry.
Used in Chemical Suppliers and Manufacturers:
As a specialized chemical compound, 2-Bromo-5-fluoropyrimidine is typically sold and acquired through chemical suppliers and manufacturers. These entities play a crucial role in providing researchers and industries with the necessary materials to conduct experiments and develop new products, further expanding the potential applications of this versatile compound.
Check Digit Verification of cas no
The CAS Registry Mumber 947533-45-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,7,5,3 and 3 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 947533-45:
(8*9)+(7*4)+(6*7)+(5*5)+(4*3)+(3*3)+(2*4)+(1*5)=201
201 % 10 = 1
So 947533-45-1 is a valid CAS Registry Number.
InChI:InChI=1/C4H2BrFN2/c5-4-7-1-3(6)2-8-4/h1-2H
947533-45-1Relevant academic research and scientific papers
INHIBITORS OF HISTONE DEACETYLASE
-
Paragraph 00193, (2020/02/06)
Provided herein are compounds of the Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone deacetylases (HDAC).
NOVEL GALACTOSIDE INHIBITOR OF GALECTINS
-
Page/Page column 51; 52, (2016/08/10)
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 44, (2012/03/12)
Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
